SHERIDAN, WYOMING - April 9, 2026 - Federal grant programs that nearly 90 percent of small medtech companies rely on for early-stage R&D funding lapsed on September 30, 2025, and their restoration now hinges on House action following the Senate's passage of reauthorization legislation for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
What the SBIR and STTR programs do
The SBIR and STTR programs distribute competitive grants through 11 federal agencies - including the National Institutes of Health, the National Science Foundation, and the Department of Defense - specifically to small businesses and startups developing early-stage technologies. For medtech, these grants bridge the funding gap between initial concept development and the commercially financeable stages of product development, where venture capital and private equity rarely engage.
The programs' lapse left hundreds of small medtech companies without access to funding mechanisms they had integrated into their R&D planning cycles. Among AdvaMed's more than 600 member companies - the majority of which are emerging or small businesses represented through its AdvaMed Accel division - 89 percent reported applying for SBIR or STTR grants, with 31 percent successfully securing funding. That breadth of participation underscores how structurally embedded these grants are in small medtech innovation pipelines.
Senate action and the path to full restoration
The Senate approved reauthorization legislation in a bipartisan vote, advancing the bill with support from both sides of the aisle. The legislation had backing from Sen. Joni Ernst, chair of the Senate Committee on Small Business and Entrepreneurship, and Sen. Ed Markey, the committee's ranking member. On the House side, parallel engagement involves Rep. Roger Williams, chairman of the House Committee on Small Business; Rep. Lydia Velázquez, ranking member; Rep. Brian Babin, chairman of the House Committee on Science, Space and Technology; and Rep. Zoe Lofgren, ranking member.
AdvaMed, the Medtech Association, has urged the House to act quickly. Until the House passes the legislation and it is signed into law, the authorization gap - now more than six months old - continues to create uncertainty for startups that were planning grant applications or managing existing award pipelines when the programs expired.
Innovation and workforce implications
SBIR and STTR grants do not simply fund product prototypes; they sustain research teams, support regulatory feasibility studies, and enable small manufacturers to generate the preclinical and early clinical data needed to attract follow-on private investment. The programs operate across a broad set of therapeutic and diagnostic categories, meaning the innovation gap created by the lapse extends beyond any single device class or patient population.
Small medtech businesses, unlike large device manufacturers, typically lack the balance-sheet depth to absorb multi-quarter funding interruptions. Extended program lapses compress timelines, delay hiring, and in some cases force founders to divert resources from product development toward bridge financing - all of which slow the path from bench to regulatory submission.
Business impact
Startup founders and early-stage medtech CEOs face immediate decisions around grant application timing and R&D budget allocation. With Senate passage secured but House action still pending, companies that paused SBIR and STTR applications during the lapse should not assume funding access is restored - full reauthorization requires enacted legislation, not Senate passage alone.
Procurement leads and supply chain officers at contract research organizations and device manufacturers that partner with SBIR-funded startups should treat the legislative timeline as a vendor pipeline risk variable. Delays in small-company R&D caused by the funding gap can push collaboration timelines and milestone-based contract structures into later quarters. Investors and venture capital firms evaluating seed and Series A medtech deals in 2026 should factor reauthorization status into due diligence, since SBIR and STTR co-funding assumptions embedded in startup financial models remain contingent on enacted law.